Ms Vicky McGrath:

It comes down to whether we are willing to even pay the price BeNeLuxA has negotiated. I do not know. In the very short term, as patients and patient organisations, the big thing we would like to see happen is an opening up of the relationship between pharma and the HSE. Things go into the black box - I think "opaque" is a nice word to use - but there is no visibility and one, two or three years could pass by. We hear anecdotally from the industry which is far more willing to discuss this issue than not that it has had a meeting, or not as the case may be, or a phone call, or that an email was sent in the intervening period. That there is no visibility is one of the biggest challenges we face in the short term and it would be easy to address, to at least say in broad terms that there was communication, or that a meeting was held and that people promised to come back in three months' time. That would help us a lot in the short term. We would then look at rebuilding the systems and stuff like that.